Confo Therapeutics, an emerging drug discovery company, has entered into a research collaboration and license agreement with Roche for the discovery, development, and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders. Under the terms of the agreement, Roche gains exclusive rights to…